SLC5A2 and diabetes mellitus: While this approach allowed for a more specific evaluation of the independent effect of SGLT2 inhibitors, it may have introduced selection bias by preferentially retaining patients with less severe DM, who are more likely to receive monotherapy and inherently have a lower risk of TB.